News | November 11, 2024
Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
Hospital business revenues increase 13.9% to Rs. 1,655 crore
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
This product will be manufactured at Lupin’s Nagpur facility in India
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
